{'fraction_non_alphanumeric': 0.04006497022198159, 'fraction_numerical': 0.028153762858689767, 'mean_word_length': 5.553191489361702, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 1, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Thrombocytopenia associated with human immunodeficiency virus infection. Pathogenic significance of platelet autoimmunity phenomena].

OBJECTIVES
Several mechanisms in formation and destruction of platelets could be involved in thrombocytopenia associated with HIV infection (TP/HIV). This epidemiological study investigated the pathogenic role of immunoglobulins associated with platelets (IAP), circulant immunocomplexes (CIC) and anticardiolipin antibodies (ACA) in patients with TP/HIV:


PATIENTS AND METHODS
A total of 207 adults patients infected with HIV were studied. Patients were classified as thrombocytopenic (platelet count < 100,000/mm3, n = 68); borderline thrombocytopenic (platelet count from 100,000 to 150,000/mm3, n = 23) and non-thrombopenic (platelet count > 150,000/m3, n = 116). IAP were investigated by an immunofluorescence technique with flow cytometry reading and eluate technique. CIC were investigated by C1q fixation measured by nephelometry. IgG-ACA determination was made with a commercially available ELISA technique.


RESULTS
Prevalence of thrombocytopenia in the general cohort of seropositive patients was 16%. Fifteen per cent of these patients had severe TP. There were no significant differences in epidemiology or prognosis among patients with and without TP. Patients with TP/HIV had increase rates of IAP, CIC and ACA (78%, 42% and 89%). These parameters were also increased in a similar percentage of non-TP infected patients (73%, 52%, 94% respectively). No correlation was observed between platelet counts and values of these immunological phenomena.


CONCLUSIONS
TP/HIV is common, mild, with no prognostic significance and occurs in an heterogeneous patient population. Immune phenomena associated with a decreased platelet survival occur nonspecifically and with an uncertain pathogenic meaning.